Jeffrey Allan Rihn, M.D. Orthopaedic Surgery - Orthopaedic Surgery of the Spine Medicare: Accepting Medicare Assignments Practice Location: 650 Carnegie Blvd Fl 2, Malvern, PA 19355 Phone: 267-339-3558 Fax: 267-339-3763 |
Rachel Gittler, PAC Orthopaedic Surgery Medicare: Medicare Enrolled Practice Location: 266 Lancaster Ave Ste 200, Malvern, PA 19355 Phone: 610-644-6900 Fax: 610-644-7160 |
Charles J Odgers, M.D. Orthopaedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 266 Lancaster Ave, Suite 200, Malvern, PA 19355 Phone: 610-644-6900 Fax: 610-644-7160 |
Dr. Ashley Hannah Anderson, MD Orthopaedic Surgery - Sports Medicine Medicare: Accepting Medicare Assignments Practice Location: 266 Lancaster Ave, 200, Malvern, PA 19355 Phone: 610-644-6900 Fax: 610-644-4708 |
Jonathan P Garino, MD Orthopaedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 266 Lancaster Ave, Suite 200, Malvern, PA 19355 Phone: 610-644-6900 Fax: 610-644-7160 |
Itai Gans, M.D. Orthopaedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 266 Lancaster Ave Ste 200, Malvern, PA 19355 Phone: 610-644-6900 Fax: 610-644-7160 |
News Archive
This week's issue of the Lancet "has an HIV theme ahead of the International AIDS Society meeting in Washington, D.C., ... on July 22-27," a Lancet editorial states, noting, "The issue of antiretrovirals for prevention, specifically pre-exposure prophylaxis, is presently under intense debate."
Drawing on genomic data from more than one million individuals, researchers from the University of Michigan have led a large collaborative effort to discover as-yet unknown genetic risk factors for atrial fibrillation: an irregular, often rapid heart rate affecting millions of Americans and more than 30 million people worldwide.
Human cytomegalovirus may not be a household name as far as viruses go, but according to Xiaoping Zhu, professor and chair in Veterinary Medicine at UMD, half of the population walking around campus is likely to be a carrier.
Ember Therapeutics, Inc., a company harnessing breakthroughs in brown fat biology and insulin sensitization to revolutionize the treatment of metabolic disease, today announced the publication of key preclinical data demonstrating that inhibition of the Transient Receptor Potential Vanilloid (TRPV) family of ion channels - specifically TRPV4 - resulted in activation of brown/beige fat and protection from diet-induced obesity, inflammation and insulin resistance. Ember holds an exclusive option to license these TRPV4 findings and technology.
The Department of Justice takes the position that the Florida judge's ruling in which he threw out the health law is "indefensible."
› Verified 9 days ago